Articles

Single-dose IV Regimen Comparable with 3-Day Regimen for Prevention of CINV

October 2010, Vol. 3, No 7

CHICAGO—Findings of a new study suggest that an antiemetic regimen containing a single intravenous (IV) 150- mg dose of fosaprepitant dimeglumine in combination with a 5-hydroxytryptamine type 3 (5-HT3) antagonist and dexamethasone appears to be comparable with a 3-day regimen of aprepitant with a 5-HT3 antagonist and dexa methasone for the prevention of chemo - therapy-induced nausea and vomiting (CINV).

October 2010, Vol. 3, No 7

CHICAGO—Among patients with lung cancer on highly emetogenic chemo therapy, those receiving palo - nosetron throughout all cycles of chemo therapy had a 31% lower risk of chemo therapy-induced nausea and vomiting (CINV) associated with an emergency department or hospital visit, than patients receiving other 5- hydroxy tryptamine type 3 (5-HT3) re - ceptor antagonists (RAs).

By Michael Auerbach, MD

Web Exclusives

The role of intravenous (IV) iron as an addition to erythropoiesis-stimulating agents (ESAs) to optimize therapy in patients with anemia from cancer or chemotherapy-induced anemia has been examined in nine prospective, randomized trials,1-9 all of which showed improvement in ESA response, time to maximal response, reduction in ESA dose to reach maximal response, and improvement in quality-oflife parameters (when measured).

TOP - Daily

Patient adherence to colorectal cancer (CRC) screening guidelines remains suboptimal, particularly among minorities. Two new studies suggest ways to increase screening rates.

One study, by Moshe Shike, MD, of Memorial Sloan-Kettering Cancer Center, New York, and associates found that offering CRC screening during mammography visits is “an effective way of generating interest and initiating the process” in minority women. The results are reported online in Cancer.

Supportive Care

TOP - Daily

A new intervention designed to help mothers cope with the stresses associated with their child’s cancer appears to be more effective long term compared with other psychological approaches, according to a study reported at the 42^nd Congress of the International Society of Pediatric Oncology.

TOP - Daily

Patients with chronic myeloid leukemia (CML) who have maintained complete molecular remission (CMR) for at least 2 years can safely discontinue imatinib therapy, French researchers report.

TOP - Daily

Many patients diagnosed with skin cancer do not know whether they have melanoma or nonmelanoma skin cancer and, as a result, may have a poor sense of the measures they need to take to reduce the risk of future skin cancers, a

TOP - Daily

In a long-term study of men who underwent robot-assisted radical prostatectomy (RARP) nearly 87% had no recurrence of the disease after 5 years.

The study cohort included 1384 men who were diagnosed with moderately aggressive localized prostate cancer and underwent RARP between September 2001 and May 2005 at a tertiary center. Their average age was 60 years.

TOP - Daily

Researchers identified an association between type 2 diabetes and colorectal cancer (CRC) among men. The association did not hold for women. The new study, published in the October issue of Gastroenterology, found that the risk existed regardless of insulin use. Insulin use, in fact, was found to be associated with a slight but not substantially increased risk of CRC.

TOP - Daily

Use of hospice care for men with prostate cancer has increased significantly over the past 2 decades, but most wait too long to enroll, when they cannot take full advantage of the palliative care services offered, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.

Articles

Page 272 of 289